

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Single Technology Appraisal

Pembrolizumab with pemetrexed and platinum-based chemotherapy for untreated unresectable advanced malignant pleural mesothelioma ID4044

Provisional Stakeholder List

Consultees	Commentators (no right to submit or
	appeal)
 Merck Sharpe and Dohme (pembrolizumab) Patient/carer groups Asbestos Victims Support Groups Forum UK Asthma and Lung UK Black Health Agency for Equality Cancer 52 Cancer Black Care Cancer Equality Helen Rollason Cancer Charity Independent Cancer Patients Voice John MacDougall Mesothelioma Trust Macmillan Cancer Support Maggie's Centres Marie Curie Mesothelioma UK Roy Castle Lung Cancer Foundation South Asian Health Foundation Specialised Healthcare Alliance Tenovus Cancer Care UK Lung Cancer Coalition 	 General All Wales Therapeutics and Toxicology Centre Allied Health Professionals Federation Board of Community Health Councils in Wales British National Formulary Care Quality Commission Department of Health, Social Services and Public Safety for Northern Ireland GMB - Britain's General Union Health and Safety Executive Healthcare Improvement Scotland Joint Union Asbestos Committee Medicines and Healthcare products Regulatory Agency National Association of Primary Care National Pharmacy Association NHS Confederation Scottish Medicines Consortium UK Asbestos Training Association Welsh Government Welsh Health Specialised Services Committee
 Healthcare professional groups Association of Cancer Physicians Association of Respiratory Nurse British Geriatrics Society British Institute of Radiology British Oncology Pharmacy Association British Psychosocial Oncology Society 	 Possible comparator companies Aspire Pharma (pemetrexed) Bristol Myers Squibb (ipilimumab, nivolumab) Dr. Reddy's Laboratories (UK) (pemetrexed) Eli Lilly (pemetrexed) Genus (pemetrexed)
British Psychosocial Oncology SocietyBritish Thoracic Oncology Group	Genus (pemetrexed)Hospira (carboplatin, cisplatin)

Provisional stakeholder list for evaluation of pembrolizumab with pemetrexed and platinum-based chemotherapy for untreated unresectable advanced malignant pleural mesothelioma ID4044 Issue date: January 2024



Consultees	Commentators (no right to submit or
	appeal)
 British Thoracic Society Cancer Research UK Lung Cancer and Mesothelioma Clinical Expert Group Lung Cancer Nursing UK National Heart and Lung Institute Primary Care Respiratory Society Royal College of General Practitioners Royal College of Nursing Royal College of Pathologists Royal College of Physicians Royal College of Radiologists Royal Pharmaceutical Society Royal Society of Medicine Society and College of Radiographers Specialists UK Clinical Pharmacy Association UK Oncology Nursing Society 	 Pfizer (pemetrexed) Ranbaxy (UK) (pemetrexed) Sandoz (cisplatin, pemetrexed) Seacross Pharmaceuticals (pemetrexed) Zentiva (pemetrexed) Relevant research groups Bart's Mesothelioma Research Cochrane Lung Cancer Group Cochrane UK Genomics England Institute of Cancer Research June Hancock Mesothelioma Research Fund MRC Clinical Trials Unit National Institute for Health Research
OthersDepartment of Health and Social CareNHS England	Associated Public Health groupsPublic Health WalesUK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.


Definitions:

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

Provisional stakeholder list for evaluation of pembrolizumab with pemetrexed and platinum-based chemotherapy for untreated unresectable advanced malignant pleural mesothelioma ID4044 Issue date: January 2024



All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.